Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16424839 | 0.86 | CA1 (0.52) | SIRT2SIRT1SIRT3SIRT5CA1 | |
| SCHEMBL31726507 | 0.84 | CA1 (0.50) | SIRT2SIRT1SIRT3SIRT5CA1 | |
| SCHEMBL21566843 | 0.84 | SIRT1 (0.41) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22283146 | 0.83 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL21450347 | 0.83 | CA2 (0.49) | SIRT1SIRT5CA1CA2MMP3 | |
| SCHEMBL12944390 | 0.81 | NPY4R (0.38) | SIRT1 | |
| SCHEMBL84332 | 0.81 | NPY4R (0.38) | SIRT1 | |
| SCHEMBL16770343 | 0.81 | SIRT1 (0.39) | SIRT2SIRT1SIRT3SIRT5CA1 | |
| SCHEMBL20739105 | 0.81 | NPY4R (0.38) | SIRT1 | |
| SCHEMBL22315797 | 0.81 | NPY4R (0.38) | SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-12 | — | — | US | disclosed |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-3690038-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | SIRT2 3961/4885SIRT1 4543/4885SIRT3 4109/4885 |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SIRT2 4173/4885SIRT1 4618/4885SIRT3 4105/4885 |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | GABRA1, GABRA4, GABRA2 | SIRT2 2736/4885SIRT1 2918/4885SIRT3 4011/4885 |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SIRT2 4173/4885SIRT1 4618/4885SIRT3 4105/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | SIRT2 4512/4885SIRT1 4729/4885SIRT3 4573/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SIRT2 4173/4885SIRT1 4618/4885SIRT3 4105/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | SIRT2 4038/4885SIRT1 4192/4885SIRT3 4225/4885 |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SIRT2 4173/4885SIRT1 4618/4885SIRT3 4105/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | SIRT2 4068/4885SIRT1 4219/4885SIRT3 4258/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | SIRT2 4275/4885SIRT1 4706/4885SIRT3 4442/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SIRT2 4173/4885SIRT1 4618/4885SIRT3 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.